Literature DB >> 12582229

Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia.

Judith Korner, Janet Lo, Pamela U Freda, Sharon L Wardlaw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12582229     DOI： 10.1038/oby.2003.46

Source DB:  PubMed          Journal:  Obes Res        ISSN： 1071-7323


× No keyword cloud information.
  15 in total

Review 1.  The Interplay Between Pituitary Health and Diabetes Mellitus - The Need for 'Hypophyseo-Vigilance'.

Authors:  Saptarshi Bhattacharya; Sanjay Kalra; Deep Dutta; Deepak Khandelwal; Rajiv Singla
Journal:  Eur Endocrinol       Date:  2019-10-18

2.  Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults.

Authors:  C D Gibson; W Karmally; D J McMahon; S L Wardlaw; J Korner
Journal:  Diabetes Obes Metab       Date:  2011-12-27       Impact factor: 6.577

3.  Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism.

Authors:  Andras Kern; Rosie Albarran-Zeckler; Heidi E Walsh; Roy G Smith
Journal:  Neuron       Date:  2012-01-26       Impact factor: 17.173

4.  Metabolic syndrome associated with hyperprolactinemia: a new indication for dopamine agonist treatment?

Authors:  Ignacio Bernabeu; Felipe F Casanueva
Journal:  Endocrine       Date:  2013-08-22       Impact factor: 3.633

5.  The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.

Authors:  A P Athanasoulia; C Sievers; M Uhr; M Ising; G K Stalla; H J Schneider
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

6.  Intranasal cabergoline: pharmacokinetic and pharmacodynamic studies.

Authors:  Gitanjali Sharma; Anil Kumar Mishra; Pushpa Mishra; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2009-11-06       Impact factor: 3.246

7.  Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term.

Authors:  Lukas Andereggen; Janine Frey; Robert H Andres; Markus M Luedi; Jan Gralla; Gerrit A Schubert; Jürgen Beck; Luigi Mariani; Emanuel Christ
Journal:  J Clin Transl Endocrinol       Date:  2021-06-17

8.  Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.

Authors:  Adele Bahar; Zahra Kashi; Ezzatossadat Daneshpour; Ozra Akha; Shahram Ala
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

9.  Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment.

Authors:  Muzaffar Ali; Lubna Mirza
Journal:  AACE Clin Case Rep       Date:  2021-03-11

Review 10.  Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Authors:  Anastasia P Athanasoulia-Kaspar; Kathrin H Popp; Gunter Karl Stalla
Journal:  Endocr Connect       Date:  2018-01-29       Impact factor: 3.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.